Davide Brogi

Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies

M. Ulivelli, G. Marfia, M. Sormani, 2021, EBioMedicine.

Early switch to fingolimod may decrease the risk of disease recurrence after natalizumab interruption

A. Uccelli, G. Mancardi, G. Mancardi, 2013, Multiple sclerosis.

Fingolimod Modulates Peripheral Effector and Regulatory T Cells in MS Patients

L. Serpero, A. Uccelli, G. Mancardi, 2013, Journal of Neuroimmune Pharmacology.

Understanding Factors Associated With Psychomotor Subtypes of Delirium in Older Inpatients With Dementia.

P. Mazzanti, C. Mussi, D. Cucinotta, 2020, Journal of the American Medical Directors Association.

Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial

C. Pozzilli, G. Comi, V. Morra, 2014, BMC Neurology.

Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in Italy

C. Pozzilli, G. Comi, A. Lugaresi, 2016, Neurological Sciences.

Understanding Factors Associated With Psychomotor Subtypes of Delirium in Older Inpatients With Dementia.

P. Mazzanti, C. Mussi, D. Cucinotta, 2020, Journal of the American Medical Directors Association.